• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2023 Jan;29(1):226-228.
doi: 10.3201/eid2901.221514.
Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021

Stephanie J Curtis, Abdul W Shah, Ana Ratu, Donald J Wilson, Philip C Hill, Phil Hulcome, Cathy Gaylard, Daniel Faktaufon, Talica Cabemaiwai, Isireli Rabukawaqa, Tevita Qoriniasi, Akesh Narayan, Susana Nakalevu, Pablo Romakin, Jemesa Tudravu, James Fong, Nick Walsh

Abstract

During November-December 2021, we performed a SARS-CoV-2 seroprevalence survey in Central and Western Divisions of Fiji. A total of 539 participants 8-70 years of age were 95.5% (95% CI 93.4%-97.1%) seropositive, indicating high community levels of immunity. Seroprevalence studies can inform public health responses to emerging SARS-CoV-2 variants.

Keywords: COVID-19; Fiji; Pacific Islands; SARS; SARS-CoV-2; antibodies; coronavirus; coronavirus disease; disease outbreak; respiratory infections; seroepidemiologic studies; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom